Michael Olsen, MD
Family Medicine · Vernal, UTNPI 1356437891
Payments from drug & device makers
Across 171 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$592
- Lilly USA, LLC$252
- Novo Nordisk$237
- AbbVie$210
- Amgen$164
- Pfizer$117
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,595100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $592 |
| Lilly USA, LLC | 17 | $252 |
| Novo Nordisk | 31 | $237 |
| AbbVie(2 entities) | 11 | $210 |
| Amgen | 7 | $164 |
| Pfizer | 8 | $117 |
| Boehringer Ingelheim | 7 | $109 |
| Dexcom, Inc. | 6 | $103 |
| Corcept Therapeutics | 6 | $96 |
| Abbott | 5 | $83 |
| Organon | 3 | $64 |
| Merck | 4 | $61 |
| Actelion Pharmaceuticals US, Inc. | 3 | $56 |
| Novartis | 3 | $50 |
| Amarin Pharma, Inc. | 3 | $48 |
| Johnson & Johnson | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| GSK | 2 | $29 |
| Astellas Pharma US Inc | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| BETA Bionics, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
How this compares
$2,595 in reported general payments places this provider in the 75th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $89,303 |
| Daptomycin | 24 | $74,674 |
| FarxigaDapagliflozin Propanediol | 56 | $70,403 |
| TrulicityDulaglutide | 64 | $68,016 |
| OzempicSemaglutide | 65 | $65,934 |
| JardianceEmpagliflozin | 68 | $52,478 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 98 | $50,703 |
| JanuviaSitagliptin Phosphate | 58 | $32,560 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $30,877 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $23,971 |
| XareltoRivaroxaban | 30 | $22,790 |
| VraylarCariprazine Hcl | 26 | $18,820 |
| TradjentaLinagliptin | 11 | $16,645 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $11,740 |
| LinzessLinaclotide | 16 | $11,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $117 | $89,303107 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Arnuity Ellipta | $29 | $83,972142 claims |
| AstraZenecaFarxiga | $592 | $70,40356 claims |
| Boehringer IngelheimJardiance, Tradjenta | $109 | $69,12379 claims |
| Lilly USA, LLCTrulicity | $252 | $68,01664 claims |
| Novo NordiskOzempic | $237 | $65,93465 claims |
| MerckJanuvia | $61 | $32,56058 claims |
| AbbVieVraylar, Linzess | $210 | $30,06642 claims |
| Johnson & JohnsonXarelto | $44 | $22,79030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 928 family medicine providers in Utah.
Other family medicine in Vernal
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
- Scott EricksonBountiful$3.7M
- John RichardsSouth Jordan$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.